These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 11074389

  • 1. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [Abstract] [Full Text] [Related]

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 3. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [Abstract] [Full Text] [Related]

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.
    Health Technol Assess; 2001 Oct; 5(28):1-110. PubMed ID: 11701100
    [Abstract] [Full Text] [Related]

  • 5. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [Abstract] [Full Text] [Related]

  • 6. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
    Benedict A, Cameron DA, Corson H, Jones SE.
    Pharmacoeconomics; 2009 Mar; 27(10):847-59. PubMed ID: 19803539
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G.
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE, Hutton J, Burrell A.
    Pharmacoeconomics; 2001 Oct; 19(11):1091-102. PubMed ID: 11735676
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM, Wiseman LR.
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Oct; 19(12):1227-59. PubMed ID: 11772158
    [Abstract] [Full Text] [Related]

  • 12. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ, Reboul-Marty JM, Bonneterre J.
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [Abstract] [Full Text] [Related]

  • 13. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R, Reboul-Marty J, Henry B, Bonneterre J.
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro MS, Alaki M, Murawsky M, Riva A.
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A.
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV.
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [Abstract] [Full Text] [Related]

  • 17. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB, Valero V, Hortobagyi G.
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [Abstract] [Full Text] [Related]

  • 18. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
    Lynch TJ.
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):5-9. PubMed ID: 11444253
    [Abstract] [Full Text] [Related]

  • 19. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S.
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP, Wiseman LR.
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.